A Rare Case of De novo C634G Germline Mutation of the RET Proto-Oncogene in a Patient With MEN 2A Syndrome With Aggressive Pheochromocytoma

Laurentiu M Pop, Shirley X. Yan, Ildiko Lingvay

Abstract


Multiple endocrine neoplasia type 2A (MEN 2A) is an autosomal inherited disorder induced by mutations in the RET proto-oncogene. It is characterized by medullary thyroid carcinoma (MTC), accompanied in half of cases by pheochromocytoma and less frequently, by primary hyperparathyroidism. The aim of the study was to investigate a clinical case of a MEN 2A syndrome consisting of bilateral aggressive pheochromocytomas and MTC with loco-regional lymph node invasion caused by a rare de novo germline mutation in the RET proto-oncogene (Cys634Gly). We reported herein a 42-year-old man presented with hypertension refractory to various antihypertensive drug regimens administered over the preceding 3 years. Abdominal computed tomography scan showed a large right adrenal mass, and a smaller left adrenal nodule. Comprehensive biochemical analyses (24-hour urinary catecholamines and metabolites) confirmed the diagnosis of pheochromocytoma. 123I-metaiodobenzylguanidine scintigraphy revealed uptake in the left inferior thyroid nodule. Left thyroid ultrasound-guided fine needle aspiration established the diagnosis of MTC. The patient first underwent open right adrenalectomy, and 2 months later, total thyroidectomy with central neck compartment lymph node dissection. Screening for hyperparathyroidism was negative. On follow-up, the patient demonstrated no biochemical abnormalities, or clinical complaints. Genetic testing identified a point mutation in the RET proto-oncogene, confirming the diagnosis of MEN 2A. This missense mutation, located in exon 11, resulted in the replacement of a cysteine 634 residue with glycine.

To the best of our knowledge, this is the first MEN 2A case reported with de novo Cys634Gly RET germline mutation in North America, and also worldwide with regard to the aggressiveness of this genotypic variant.





J Endocrinol Metab. 2012;2(4-5):198-204
doi: https://doi.org/10.4021/jem120w

Keywords


MEN 2A; RET proto-oncogene Cys634Gly mutation; Aggressive pheochromocytoma

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.


Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.